SET protein inhibition blocks glioblastoma tumor formation in preclinical models

Researchers have identified a potential new method to undermine glioblastoma’s resistance to therapy by targeting the protein SET. In preclinical studies, inhibition of SET halted tumor formation, and simultaneous disruption of related proteins increased the susceptibility of glioblastoma cells to radiation treatment.

The approach functions by reactivating protein phosphatase 2A (PP2A), an enzyme that glioblastoma cells typically suppress to promote survival. Restoring PP2A activity appears to compromise the cancer’s defensive mechanisms, allowing conventional treatments such as radiation to be more effective in laboratory models.

While the findings demonstrate promising anti‑tumor effects in animal and cellular experiments, further investigation is required to assess safety and efficacy in humans before the strategy can be considered for clinical application.